CED Clinical Trials

1 recruiting

CED Trials at a Glance

2,267 actively recruiting trials for ced are listed on ClinicalTrialsFinder across 6 cities in 85 countries. The largest study group is Phase 1 with 915 trials, with the heaviest enrollment activity in Houston, Shanghai, and New York. Lead sponsors running ced studies include National Cancer Institute (NCI), M.D. Anderson Cancer Center, and Jiangsu HengRui Medicine Co., Ltd..

Treatments under study

About CED Clinical Trials

Looking for clinical trials for CED? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new CED trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about CED clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 2,267 trials

Recruiting
Phase 2

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

Recurrent Lung Non-Small Cell CarcinomaAdvanced Lung Non-Small Cell CarcinomaStage IIIB Lung Non-Small Cell Cancer AJCC v7+1 more
National Cancer Institute (NCI)46 enrolled344 locationsNCT03191149
Recruiting
Phase 2

T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer

Squamous Cell CarcinomaAdvanced Non-Small Cell Lung CancerAdvanced NSCLC+2 more
National Cancer Institute (NCI)85 enrolled1 locationNCT02133196
Recruiting
Phase 2

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Malignant Female Reproductive System Neoplasm+12 more
National Cancer Institute (NCI)2,900 enrolled479 locationsNCT05564377
Recruiting
Phase 2Phase 3

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8+13 more
National Cancer Institute (NCI)224 enrolled370 locationsNCT06203600
Recruiting
Phase 2

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

Lung Neuroendocrine NeoplasmAdvanced Lung Neuroendocrine TumorFunctioning Lung Neuroendocrine Tumor+9 more
National Cancer Institute (NCI)70 enrolled29 locationsNCT04665739
Recruiting

A Natural History Study of Bone and Mineral Disorders

Tumor Induced OsteomalciaOsteomalaciaFamilial Tumoral Calcinosis
National Institute of Dental and Craniofacial Research (NIDCR)1,000 enrolled1 locationNCT00024804
Recruiting
Phase 2Phase 3

Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

Advanced Extrapulmonary Neuroendocrine CarcinomaMetastatic Extrapulmonary Neuroendocrine CarcinomaRecurrent Extrapulmonary Neuroendocrine Carcinoma+1 more
National Cancer Institute (NCI)189 enrolled244 locationsNCT05058651
Recruiting
Phase 1Phase 2

A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

Advanced or Metastatic Non-small Cell Lung Cancer
AstraZeneca152 enrolled104 locationsNCT06996782
Recruiting
Phase 2

A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)

Advanced Renal Cell Carcinoma (aRCC)
Brian Rini120 enrolled1 locationNCT07188896
Recruiting
Phase 3

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

Stage IIIA Cervical Cancer FIGO 2018Stage IIIB Cervical Cancer FIGO 2018Locally Advanced Cervical Adenocarcinoma+5 more
National Cancer Institute (NCI)336 enrolled222 locationsNCT07061977
Recruiting
Phase 3

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

Advanced Endometrial CarcinomaRecurrent Endometrial Carcinoma
National Cancer Institute (NCI)255 enrolled147 locationsNCT07198074
Recruiting
Phase 1Phase 2

Study in Advanced Solid Tumor Patients

Advanced Solid Tumor
Callio Therapeutics306 enrolled11 locationsNCT07300943
Recruiting
Phase 1

Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer

Locally Advanced Pancreatic CarcinomaStage II Pancreatic Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8+1 more
National Cancer Institute (NCI)18 enrolled11 locationsNCT05411094
Recruiting
Phase 1Phase 2

A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours

Metastatic Solid TumorLocally Advanced Solid Tumor
Ipsen114 enrolled12 locationsNCT07213817
Recruiting
Phase 3

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitean-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

Locally Advanced Urothelial CarcinomaMetastatic Urothelial CarcinomaUnresectable Urothelial Carcinoma
National Cancer Institute (NCI)320 enrolled129 locationsNCT06524544
Recruiting
Phase 1

A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma

Advanced Unresectable Hepatocellular Carcinoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.36 enrolled2 locationsNCT07478302
Recruiting
Phase 1Phase 2

A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.

Locally Advanced Pancreatic AdenocarcinomaLocally Advanced Pancreas CancerLocally Advanced Pancreatic Ductal Adenocarcinoma
Xerient Pharma36 enrolled4 locationsNCT07157033
Recruiting
Phase 1

A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma

Metastatic Hepatocellular CarcinomaAdvanced Hepatocellular Carcinoma
Alnylam Pharmaceuticals158 enrolled23 locationsNCT06600321
Recruiting
Phase 1

A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)

Advanced Relapsed or Refractory Germ Cell TumoursAdvanced Relapsed or Refractory Endometrial CancerAdvanced Relapsed or Refractory Ovarian Cancer
Boehringer Ingelheim187 enrolled13 locationsNCT07306559
Recruiting
Phase 3

Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)

Locally Advanced Cervical Cancer
AstraZeneca800 enrolled204 locationsNCT06079671